DE602005027714D1 - Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität - Google Patents

Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität

Info

Publication number
DE602005027714D1
DE602005027714D1 DE602005027714T DE602005027714T DE602005027714D1 DE 602005027714 D1 DE602005027714 D1 DE 602005027714D1 DE 602005027714 T DE602005027714 T DE 602005027714T DE 602005027714 T DE602005027714 T DE 602005027714T DE 602005027714 D1 DE602005027714 D1 DE 602005027714D1
Authority
DE
Germany
Prior art keywords
memantine
treatment
autism
namenda
impulsivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005027714T
Other languages
English (en)
Inventor
Eric Hollander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of DE602005027714D1 publication Critical patent/DE602005027714D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE602005027714T 2004-09-20 2005-09-19 Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität Active DE602005027714D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61153404P 2004-09-20 2004-09-20
PCT/US2005/033467 WO2006034187A2 (en) 2004-09-20 2005-09-19 Use of memantine (namenda) to treat autism, compulsivity, and impulsivity

Publications (1)

Publication Number Publication Date
DE602005027714D1 true DE602005027714D1 (de) 2011-06-09

Family

ID=36090565

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005027714T Active DE602005027714D1 (de) 2004-09-20 2005-09-19 Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität

Country Status (10)

Country Link
US (2) US8461148B2 (de)
EP (1) EP1793671B1 (de)
JP (1) JP5289765B2 (de)
AT (1) ATE506945T1 (de)
AU (1) AU2005286943A1 (de)
CA (1) CA2580619C (de)
DE (1) DE602005027714D1 (de)
DK (1) DK1793671T3 (de)
ES (1) ES2367868T3 (de)
WO (1) WO2006034187A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
US20080194698A1 (en) * 2005-03-07 2008-08-14 Michael Hermanussen Nmda Receptor Antagonists in the Medical Intervention of Metabolic Disorders
CA2622204C (en) 2005-09-12 2016-10-11 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same
WO2007033082A2 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
WO2007033180A1 (en) * 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
WO2007061868A2 (en) * 2005-11-17 2007-05-31 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors
WO2008063847A2 (en) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Method for treating autism
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
EP2111858A1 (de) * 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Neue Behandlung für Morbus Alzheimer
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
CN102070463A (zh) * 2009-06-11 2011-05-25 辽宁利锋科技开发有限公司 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用
JP5947721B2 (ja) 2009-10-30 2016-07-06 アベラ ファーマスーティカルズ インコーポレイテッド 変形性関節症を治療するためのジメチルスルホキシド（ｄｍｓｏ）およびメチルスルホニルメタン（ｍｓｍ）製剤
US20130018059A1 (en) * 2010-03-31 2013-01-17 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (dmso) formulations for treating autism
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
CA2870303A1 (en) * 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Organic compounds
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
BR112015012506A2 (pt) * 2012-11-28 2017-07-11 Neuren Pharmaceuticals Ltd tratamento de transtornos do espectro do autismo usando ácido glicil-l-2-metilprolil-l-glutâmico
KR101424514B1 (ko) 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP2968320B1 (de) 2013-03-15 2020-11-11 Intra-Cellular Therapies, Inc. Organische verbindungen
KR20230058736A (ko) 2013-12-03 2023-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
MX2016007612A (es) * 2013-12-13 2016-09-09 Pf Medicament Un derivado de la cromona como el antagonista del receptor de la dopamina d3 para su uso en el tratamiento del trastorno del espectro autista.
EP3125893B1 (de) 2014-04-04 2023-09-20 Intra-Cellular Therapies, Inc. Deuterierte heterozyklus-anelierte gamma-carboline als antagonisten von 5-ht2a-rezeptoren
EP3085366A1 (de) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda-antagonisten zur behandlung von mentalen erkrankungen mit auftreten von aggressivem und/oder impulsivem verhalten
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
EP3436083A4 (de) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
AU2017258303A1 (en) * 2016-04-29 2018-11-01 Supernus Pharmaceuticals, Inc. Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
IL304026A (en) 2017-03-24 2023-08-01 Intra Cellular Therapies Inc New preparations and methods
CN111093664B (zh) 2017-07-26 2023-06-02 细胞内治疗公司 有机化合物
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc organic compounds
AU2018309710A1 (en) 2017-08-01 2020-02-27 Stuart A. Lipton Methods and compositions for treating neurological conditions
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
BR112021003838A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
WO2022248621A1 (en) * 2021-05-25 2022-12-01 Awakn Ls Europe Holdings Limited Ketamine the treatment of behavioural addictions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6387956B1 (en) * 1999-03-24 2002-05-14 University Of Cincinnati Methods of treating obsessive-compulsive spectrum disorders
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CA2465869A1 (en) * 2001-11-06 2003-05-15 John L. Haracz Antimnemonic therapy for hypermemory syndromes
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism

Also Published As

Publication number Publication date
JP5289765B2 (ja) 2013-09-11
WO2006034187A2 (en) 2006-03-30
AU2005286943A1 (en) 2006-03-30
EP1793671B1 (de) 2011-04-27
WO2006034187A3 (en) 2006-09-14
US20140088083A1 (en) 2014-03-27
EP1793671A4 (de) 2008-03-12
US8461148B2 (en) 2013-06-11
EP1793671A2 (de) 2007-06-13
ES2367868T3 (es) 2011-11-10
CA2580619C (en) 2013-11-12
DK1793671T3 (da) 2011-08-22
CA2580619A1 (en) 2006-03-30
JP2008513491A (ja) 2008-05-01
ATE506945T1 (de) 2011-05-15
US20080249082A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
DE602005027714D1 (de) Verwendung von memantin (namenda) zur behandlung von autismus, zwangsverhalten und impulsivität
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE542536T1 (de) 3-ä4-(dibenzoäb,füä1,4üoxazepin-11-yl)-piperazi - 1-ylü-2,2-dimethyl propansäure zur verwendung in der behandlung von schlafstörungen
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
NO20060242L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
DE602006013945D1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
ATE554169T1 (de) Smad7-inhibitoren zur behandlung von krankheiten des zns
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE410235T1 (de) Behandlung von ballastwasser
NO20061383L (no) Substituerte aryl cykloalkanolderivater og fremgangsmater for anvendelse derav
NO20061425L (no) Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2003106656A3 (en) SINGLE-DOMAIN COMPOUNDS ASSOCIATED WITH TDF AND THE LIKE THEREOF
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE602005013805D1 (de) Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE384520T1 (de) Kombinierte verwendung von einem fibrat und von orlistat zur behandlung von obesitas
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
EA200600531A1 (ru) Сочетание ингибитора обратного захвата серотонина и локсапина
ATE516813T1 (de) Verfahren und verbindungen zur behandlung von diabetes